Published in J Biol Chem on August 19, 2003
The selectivity of protein kinase inhibitors: a further update. Biochem J (2007) 15.73
Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J (2005) 4.82
Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J (2004) 3.39
The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol (2006) 3.17
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A (2005) 2.95
Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol (2009) 2.77
Chemical inhibition of a subset of Arabidopsis thaliana GSK3-like kinases activates brassinosteroid signaling. Chem Biol (2009) 1.73
A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J (2004) 1.71
Reelin signals through phosphatidylinositol 3-kinase and Akt to control cortical development and through mTor to regulate dendritic growth. Mol Cell Biol (2007) 1.65
Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res (2006) 1.61
GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell (2010) 1.57
Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res (2008) 1.51
Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res (2012) 1.48
Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci (2011) 1.48
GSK-3 inhibitors induce chromosome instability. BMC Cell Biol (2007) 1.48
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Front Mol Neurosci (2011) 1.47
Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci (2011) 1.43
Post-translational regulation of the Drosophila circadian clock requires protein phosphatase 1 (PP1). Genes Dev (2007) 1.33
Dynamin I phosphorylation by GSK3 controls activity-dependent bulk endocytosis of synaptic vesicles. Nat Neurosci (2010) 1.33
Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest (2012) 1.32
A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest (2009) 1.32
Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br J Cancer (2009) 1.29
Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology (2008) 1.28
GSK3beta: role in therapeutic landscape and development of modulators. Br J Pharmacol (2010) 1.25
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene (2010) 1.25
Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br J Pharmacol (2007) 1.21
Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol (2013) 1.21
GSK-3β: A Bifunctional Role in Cell Death Pathways. Int J Cell Biol (2012) 1.21
GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci (2014) 1.18
Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-β precursor protein. Mol Cell Biol (2012) 1.18
Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics (2008) 1.13
GSK-3beta promotes cell survival by modulating Bif-1-dependent autophagy and cell death. J Cell Sci (2010) 1.12
Cardioprotection leads to novel changes in the mitochondrial proteome. Am J Physiol Heart Circ Physiol (2009) 1.07
Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation. Int J Biochem Cell Biol (2011) 1.06
Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome. Front Mol Neurosci (2011) 1.05
Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs (2012) 1.05
Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer (2009) 1.04
Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax. J Neurosci (2010) 1.01
Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine. J Gastroenterol (2011) 1.00
Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models. Int J Alzheimers Dis (2012) 0.99
Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2 phosphorylation and binding of Smad2 cargo. Oncogene (2011) 0.97
Leptin-dependent phosphorylation of PTEN mediates actin restructuring and activation of ATP-sensitive K+ channels. J Biol Chem (2009) 0.95
Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments. Pharmacol Ther (2013) 0.94
Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. PLoS One (2013) 0.94
The JNK- and AKT/GSK3β- signaling pathways converge to regulate Puma induction and neuronal apoptosis induced by trophic factor deprivation. PLoS One (2012) 0.93
Tau as a therapeutic target in neurodegenerative disease. Pharmacol Ther (2012) 0.92
Inhibitory phosphorylation of GSK-3 by CaMKII couples depolarization to neuronal survival. J Biol Chem (2010) 0.92
Glycogen Synthase Kinase-3beta regulates Snail and beta-catenin during gastrin-induced migration of gastric cancer cells. J Mol Signal (2010) 0.91
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma. Pigment Cell Melanoma Res (2013) 0.91
Trim17, a novel E3 ubiquitin-ligase, initiates neuronal apoptosis. Cell Death Differ (2010) 0.91
The role of tau in Alzheimer's disease and related disorders. CNS Neurosci Ther (2010) 0.91
Glycogen Synthase Kinase-3 is an Intermediate Modulator of Serotonin Neurotransmission. Front Mol Neurosci (2011) 0.90
Inhibition of tau polymerization with a cyanine dye in two distinct model systems. J Biol Chem (2009) 0.90
Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review. Eur Neuropsychopharmacol (2014) 0.90
Extremely tight binding of a ruthenium complex to glycogen synthase kinase 3. Chembiochem (2008) 0.89
Tau as a therapeutic target for Alzheimer's disease. Curr Alzheimer Res (2011) 0.89
Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease. Alzheimers Dement (2013) 0.89
Inflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer's Disease. Mediators Inflamm (2015) 0.89
The Role of Glycogen Synthase Kinase 3 Beta in Neuroinflammation and Pain. J Pharm Pharmacol (Los Angel) (2013) 0.88
Citrus flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3β enzymatic activity by lowering the interaction energy within the binding cavity. J Med Food (2011) 0.86
Corticosterone rapidly increases thorns of CA3 neurons via synaptic/extranuclear glucocorticoid receptor in rat hippocampus. Front Neural Circuits (2013) 0.86
Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer. Int J Mol Sci (2013) 0.86
Glycogen synthase kinase 3 beta regulates glial glutamate transporter protein expression in the spinal dorsal horn in rats with neuropathic pain. Exp Neurol (2013) 0.86
Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3β. J Biol Inorg Chem (2010) 0.86
Lithium protection of phencyclidine-induced neurotoxicity in developing brain: the role of phosphatidylinositol-3 kinase/Akt and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling pathways. J Pharmacol Exp Ther (2008) 0.85
p53 controls CDC7 levels to reinforce G1 cell cycle arrest upon genotoxic stress. Cell Cycle (2016) 0.85
Moderate GSK-3β inhibition improves neovascular architecture, reduces vascular leakage, and reduces retinal hypoxia in a model of ischemic retinopathy. Angiogenesis (2010) 0.84
Advances in tau-based drug discovery. Expert Opin Drug Discov (2011) 0.83
Hypothermia-induced hyperphosphorylation: a new model to study tau kinase inhibitors. Sci Rep (2012) 0.82
Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice. J Neurosci Res (2013) 0.82
Glycogen synthase kinase-3β is a functional modulator of serotonin-1B receptors. Mol Pharmacol (2011) 0.82
Epigenetic regulation of WNT signaling in chronic lymphocytic leukemia. Epigenomics (2010) 0.82
Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors. J Mol Model (2009) 0.82
Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells. Sci Rep (2015) 0.81
Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options. Oncogenesis (2015) 0.80
GSK3β inhibition promotes synaptogenesis in Drosophila and mammalian neurons. PLoS One (2015) 0.79
Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication. J Virol (2013) 0.79
Phosphorylation and mRNA splicing of collapsin response mediator protein-2 determine inhibition of rho-associated protein kinase (ROCK) II function in carcinoma cell migration and invasion. J Biol Chem (2013) 0.79
Glycogen synthase kinase-3beta (GSK-3beta) inhibitors AR-A014418 and B6B3O prevent human immunodeficiency virus-mediated neurotoxicity in primary human neurons. J Neurovirol (2009) 0.79
Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate. Brain (2016) 0.78
Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivity in CLOCK mutant mice. ChemMedChem (2011) 0.77
4-Aminoethylamino-emodin--a novel potent inhibitor of GSK-3beta--acts as an insulin-sensitizer avoiding downstream effects of activated beta-catenin. J Cell Mol Med (2009) 0.77
ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines. J Surg Res (2009) 0.77
Binding of BIS like and other ligands with the GSK-3β kinase: a combined docking and MM-PBSA study. J Mol Model (2011) 0.77
Ginger components as new leads for the design and development of novel multi-targeted anti-Alzheimer's drugs: a computational investigation. Drug Des Devel Ther (2014) 0.76
RACK1 is involved in endothelial barrier regulation via its two novel interacting partners. Cell Commun Signal (2013) 0.76
Specific serine-proline phosphorylation and glycogen synthase kinase 3β-directed subcellular targeting of stathmin 3/Sclip in neurons. J Biol Chem (2012) 0.76
Current experimental therapy for Alzheimer's disease. Curr Neuropharmacol (2007) 0.76
Small molecule suppressors of Drosophila kinesin deficiency rescue motor axon development in a zebrafish model of spinal muscular atrophy. PLoS One (2013) 0.76
CSF and Brain Indices of Insulin Resistance, Oxidative Stress and Neuro-Inflammation in Early versus Late Alzheimer's Disease. J Alzheimers Dis Parkinsonism (2013) 0.76
GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition. BMC Cancer (2016) 0.75
Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer's disease. Cell Mol Life Sci (2016) 0.75
GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions. Cell Death Dis (2016) 0.75
Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-catenin. Oncotarget (2016) 0.75
Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation. J Clin Invest (2016) 0.75
Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound-Kinase Activities: A Way toward Selective Promiscuity by Design? J Chem Inf Model (2016) 0.75
N-(4-Meth-oxy-phen-yl)-N'-(5-nitro-1,3-thia-zol-2-yl)urea. Acta Crystallogr Sect E Struct Rep Online (2010) 0.75
Colchicine-induced apoptosis was prevented by glycogen synthase kinase-3 inhibitors in PC12 cells. Cell Mol Neurobiol (2010) 0.75
Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet (2013) 3.89
Role of tau protein in both physiological and pathological conditions. Physiol Rev (2004) 2.44
Inhibition of glycogen synthase kinase 3beta during heart failure is protective. Circ Res (2007) 2.22
Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem (2004) 1.97
Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci (2003) 1.83
Mycobacterial lineages causing pulmonary and extrapulmonary tuberculosis, Ethiopia. Emerg Infect Dis (2013) 1.72
Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 1.50
Extracellular tau is toxic to neuronal cells. FEBS Lett (2006) 1.47
Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci (2006) 1.44
Biomagnification study on organochlorine compounds in marine aquaculture: the sea bass (Dicentrarchus labrax) as a model. Environ Sci Technol (2003) 1.44
Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem (2002) 1.42
Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem (2006) 1.34
Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med (2002) 1.34
Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. J Biol Chem (2006) 1.33
A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest (2009) 1.32
GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol (2009) 1.32
Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. J Alzheimers Dis (2009) 1.29
Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis (2003) 1.29
Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci U S A (2002) 1.29
Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell (2006) 1.29
Exploitation of structural and regulatory diversity in glutamate racemases. Nature (2007) 1.28
Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J Biol Chem (2003) 1.19
Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett (2011) 1.17
Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg Med Chem Lett (2005) 1.17
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis (2005) 1.16
GSK3 and tau: two convergence points in Alzheimer's disease. J Alzheimers Dis (2013) 1.15
Mycobacterium tuberculosis infection in grazing cattle in central Ethiopia. Vet J (2010) 1.15
N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem (2007) 1.15
Biosynthesis of mycobacterial lipoarabinomannan: role of a branching mannosyltransferase. Proc Natl Acad Sci U S A (2006) 1.15
Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem (2010) 1.15
A role of MAP1B in Reelin-dependent neuronal migration. Cereb Cortex (2004) 1.13
Structural features of glycosyltransferases synthesizing major bilayer and nonbilayer-prone membrane lipids in Acholeplasma laidlawii and Streptococcus pneumoniae. J Biol Chem (2002) 1.13
Zoonotic transmission of tuberculosis between pastoralists and their livestock in South-East Ethiopia. Ecohealth (2012) 1.13
Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis (2005) 1.11
Molecular characterization of Mycobacterium bovis strains isolated from cattle slaughtered at two abattoirs in Algeria. BMC Vet Res (2009) 1.11
Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem J (2003) 1.11
Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. J Neurosci (2010) 1.10
Profile of blood cells and inflammatory mediators in periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome. BMC Pediatr (2010) 1.09
The carboxy terminus of EmbC from Mycobacterium smegmatis mediates chain length extension of the arabinan in lipoarabinomannan. J Biol Chem (2006) 1.08
Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Mol Cell Biochem (2010) 1.08
The influence of cattle breed on susceptibility to bovine tuberculosis in Ethiopia. Comp Immunol Microbiol Infect Dis (2012) 1.07
Comparing illicit drug use in 19 European cities through sewage analysis. Sci Total Environ (2012) 1.07
Genetic basis for the synthesis of the immunomodulatory mannose caps of lipoarabinomannan in Mycobacterium tuberculosis. J Biol Chem (2006) 1.07
Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol Dis (2009) 1.06
Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging (2005) 1.05
Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int J Exp Pathol (2008) 1.04
Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J Neurosci (2004) 1.04
Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J (2007) 1.04
Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr Pharm Des (2010) 1.04
MAP1B is required for Netrin 1 signaling in neuronal migration and axonal guidance. Curr Biol (2004) 1.04
GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother (2007) 1.04
A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy. Arch Neurol (2005) 1.04
Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg Med Chem Lett (2005) 1.03
Glycogen synthase kinase-3 is activated in neuronal cells by Galpha12 and Galpha13 by Rho-independent and Rho-dependent mechanisms. J Neurosci (2002) 1.03
Multi-class determination of around 50 pharmaceuticals, including 26 antibiotics, in environmental and wastewater samples by ultra-high performance liquid chromatography-tandem mass spectrometry. J Chromatogr A (2011) 1.02
CHOP regulates the p53-MDM2 axis and is required for neuronal survival after seizures. Brain (2013) 1.02
Chronological primacy of oxidative stress in Alzheimer disease. Neurobiol Aging (2005) 1.02
Creating a transatlantic research enterprise for preventing Alzheimer's disease. Alzheimers Dement (2009) 1.02
African 1, an epidemiologically important clonal complex of Mycobacterium bovis dominant in Mali, Nigeria, Cameroon, and Chad. J Bacteriol (2009) 1.02
2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation. J Biol Chem (2011) 1.01
The role of GSK3 in Alzheimer disease. Brain Res Bull (2009) 1.00
MAP1B regulates microtubule dynamics by sequestering EB1/3 in the cytosol of developing neuronal cells. EMBO J (2013) 1.00
High prevalence of bovine tuberculosis in dairy cattle in central ethiopia: implications for the dairy industry and public health. PLoS One (2012) 0.99
Deconstructing mitochondrial dysfunction in Alzheimer disease. Oxid Med Cell Longev (2013) 0.99
The influence of phospho-τ on dendritic spines of cortical pyramidal neurons in patients with Alzheimer's disease. Brain (2013) 0.99
Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa. J Med Chem (2008) 0.99
GSK3β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. Hippocampus (2010) 0.99
Crystal structure and NMR studies of the apo SH2 domains of ZAP-70: two bikes rather than a tandem. Biochemistry (2002) 0.99
Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer's disease. Ann N Y Acad Sci (2005) 0.99
Alpha-helix structure in Alzheimer's disease aggregates of tau-protein. Biochemistry (2002) 0.98
The role of glycogen synthase kinase 3 in the early stages of Alzheimers' disease. FEBS Lett (2008) 0.98
Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment. Proc Natl Acad Sci U S A (2009) 0.98
Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. J Neurochem (2006) 0.98
GSK3 inhibitors and disease. Mini Rev Med Chem (2009) 0.98
Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord (2002) 0.98
European 1: a globally important clonal complex of Mycobacterium bovis. Infect Genet Evol (2011) 0.98
Role of MAP1B in axonal retrograde transport of mitochondria. Biochem J (2006) 0.97
Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease: Cross-Talk with P-tau and β-Amyloid. Front Mol Neurosci (2011) 0.97
Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. Expert Rev Neurother (2010) 0.96
Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur J Biochem (2002) 0.96
Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors. Bioorg Med Chem Lett (2004) 0.96
Total synthesis and structural confirmation of chlorodysinosin A. J Am Chem Soc (2006) 0.96
Determination of melamine in milk-based products and other food and beverage products by ion-pair liquid chromatography-tandem mass spectrometry. Anal Chim Acta (2009) 0.95
Antimicrobial susceptibility of invasive group B streptococcal isolates from south-west Sweden 1988-2001. Scand J Infect Dis (2008) 0.95